重组肠促胰岛素分泌肽对B细胞功能和胰岛素敏感性的影响研究  

Effects of Recombinant Incretin Peptide on B-cell Function and Insulin Sensitivity

作　　者：罗涌[1] 李彦[1] 刘维娟[1] 郭莲[1] 阳皓[1] 徐伟[1] 王怡[1] 王邦琼[1] 向娟[1] 

机构地区：[1]重庆三峡中心医院内分泌科,重庆404000

出　　处：《中国药房》2013年第34期3216-3218,共3页China Pharmacy

基　　金：重庆市科委项目(No.CSTC;2010AB5016);重庆市卫生局项目(No.2010-2-361);重庆市万州区科委项目(No.WZ0105007)

摘　　要：目的:研究重组肠促胰岛素分泌肽对单用磺脲类(SUs)降糖药控制不佳的2型糖尿病(T2DM)患者的治疗效果及其对B细胞功能和胰岛素敏感性的影响。方法:纳入单用SUs降糖药治疗3个月以上血糖控制不佳的T2DM患者85例,早晚餐前皮下注射重组肠促胰岛素分泌肽治疗16周。采用胰岛B细胞功能指数(HOMA-B)及早期胰岛素分泌指数(ΔI30/ΔG30)评估B细胞功能;正常血糖胰岛素钳夹试验评估胰岛素敏感性。测定治疗前后空腹血糖(FPG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)等。结果:与治疗前比较,肠促胰岛素分泌肽治疗16周后,FPG、2hPG及HbA1c均明显下降(P<0.01);ΔI30/ΔG30、HOMA-B以及胰岛素敏感指数(M/I)均显著升高(P<0.01)。结论:重组肠促胰岛素分泌肽能显著改善胰岛B细胞功能,增强胰岛素敏感性,有效治疗单药治疗疗效不佳的T2DM。OBJECTIVE：To investigate the effects of recombinant incretin peptide on poor control of blood glucose in patients with type 2 diabetics mellitus（T2DM） by sulfonylureas（SUs） alone,as well as B-cell function and insulin sensitivity.METHODS：85 T2DM patients with poor control of blood glucose after more than 3 months of SUs treatment were included.They were given hypodermic injection of recombinant incretin peptide before breakfast and supper for 16 weeks.B-cell function was evaluated by HOMA-B and early insulin secretion index（ΔI30/ΔG30）;insulin sensitivity was evaluated by euglycemic insulin clamp test.The fasting blood glucose（FPG）,2 h postprandial plasma glucose（2hPG）and glycosylated hemoglobin（HbA1 c）were all tested before and after treatment.RESULTS：Compared with baseline levels,FPG,2hPG and HbA1 c were all significantly reduced after treatment of recombinant incretin peptide for 16 weeks（P0.01）;ΔI30/ΔG30,HOMA-B and insulin sensitivity index（M/I） were all improved significantly（P0.01）.CONCLUSIONS：Recombinant incretin peptide could improve B-cell function,enhance insulin sensitivity and make better glucose control after monotherapy failure.

关 键 词：重组肠促胰岛素分泌肽 2型糖尿病 胰岛素敏感指数 胰岛B细胞功能 

分 类 号：R977.15[医药卫生—药品]